Figure 4.

Production of IFN-γ by PBMCs primed with different peptides. Peptide-primed PBMCs were exposed to irradiated EPS8-presenting HLA-A*1101⁺ K562 cells and the production of IFN-γ was detected using an ELISPOT assay. PHA treatment was used as a positive control; P0-CTLs or P-CTLs were used as negative controls. (A) Representative ELISPOT images from each condition is shown. (B) Quantification on the numbers of spot-forming cells is shown. *P<0.05 and **P<0.001, compared with the P380 group. IFN-γ interferon-γ; PBMCs, peripheral blood mononuclear cells; EPS8, epidermal growth factor receptor pathway substrate 8; HLA, human leukocyte antigen; P0, PBMCs with no peptide priming; P-CTL, PBMCs not exposed to EPS8-presenting HLA-A*1101⁺ K562 cells; ELISPOT, enzyme-linked immunospot; X–VIVO, X–VIVO15 serum-free medium; CTL, control; P, P380.